Ireland· IE-PA-PA1760/001/003
Dacarbazine Lipomed 1000 mg powder for solution for infusion
A dacarbazine product containing dacarbazine, registered in Ireland by Lipomed GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Dacarbazine is registered in 15 of 19 countries.
Countries holding a registration under ATC L01AX04 (dacarbazine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Dacarbazine · ATC L01AX04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dacarbazine costs, country by country.
Normalised to the WHO defined daily dose (43.3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dacarbazine · price per daily dose (43.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$5.12
The record
At a glance
HPRA (Ireland)- Active substance
- Dacarbazine
- Manufacturer
- Lipomed GmbH
- Country
- Ireland (IE)
- ATC code
- L01AX04
- ATC class
- Dacarbazine
- Defined daily dose
- 43.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1760/001/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
237 interactions on record for dacarbazine.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dacarbazine · interactions on record
237 records
- 35 severe
- 114 moderate
- 14 minor
- 74 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Nalidixic acidJ01MB02severe
- CladribineL01BB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dacarbazine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayDacarbazineMedac GmbH
- FinlandDacarbazine LipomedLipomed GmbH
- BelgiumDacarbazine Accord 1000 mgAccord Healthcare
- PolandDetimedac 1000 mgmedac Gesellschaft fuer klinische Spezialpraeparate mbH
- SwedenDacarbazine medac 1000 mg Pulver till infusionsvätska, lösningmedac Gesellschaft für klinische Spezialpräparate mbH
- SwitzerlandDacin 1000 mg, Pulver zur Herstellung einer InfusionslösungLipomed AG
- SpainDACARBAZINA MEDAC 1000 mg POLVO PARA SOLUCION PARA PERFUSIONMedac Gesellschaft Für Klinische Spezialpräparate Gmbh
- United KingdomDacarbazine 100mg powder for solution for injection vialsmedac UK
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Dacarbazin Lipomed, Dacarbazine Medac
- Belgium · Dacarbazine, Dacarbazine Medac
- Cyprus · Dacarbazine Lipomed
- Czechia · Dacarbazine Medac
- Germany · Dacarbazin Lipomed, Detimedac
- Denmark · Dacarbazine Lipomed, Dacarbazine Medac
- Spain · Dacarbazina Accord, Dacarbazina Medac
- Finland · Dacarbazine Lipomed, Dacarbazine Medac
- France · Dacarbazine Accord, Dacarbazine Lipomed
- United Kingdom (Northern Ireland) · Dacarbazine Medac
- Hungary · Dacarbazine Accord, Dacarbazine Lipomed
- Italy · Dacarbazina Lipomed, Dacarbazina Medac
- Netherlands · Dacarbazine Medac
- Norway · Dacarbazine Lipomed
- Poland · Detimedac
- Portugal · Dacarbazina Medac
- Romania · Dacarbazina Lipomed
- Sweden · Dacarbazine Medac
- Slovakia · Dakarbazín Medac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5e7d453b-bda1-4ac5-b23d-fd45174d8174 GET /v1/drugs/5e7d453b-bda1-4ac5-b23d-fd45174d8174?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01AX",
"L01AX04"
],
"strength": null,
"pa_number": "PA1760/001/003",
"substances": [
"Dacarbazine"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "18/08/2017",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about dacarbazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.